Two well funded 2026 launches are targeting COPD from opposite directions, one chasing inflammation, one chasing the common cold virus that keeps making it worse.
Respiratory disease has not attracted the same sustained venture attention as oncology or cardiometabolic disease in recent years, despite affecting a comparably large population. That is starting to shift, and it is shifting in two very different directions at once.
One inflammation play, one antiviral play, same disease
Two separately funded programs are advancing distinct approaches to chronic obstructive pulmonary disease this year. One is developing a long acting antibody aimed at inflammatory drivers behind conditions including asthma and COPD. The other closed an oversubscribed Series B to fund a mid-stage trial of an oral drug targeting the rhinovirus, the common cold virus, in COPD patients specifically, based on the idea that repeated viral infection is a meaningful driver of disease progression over time.
COPD has historically been treated as a single disease with a fairly narrow toolkit, bronchodilators and steroids, managing symptoms once they appear rather than addressing what is driving progression underneath them. Both of these programs represent a bet that meaningfully better outcomes require attacking those upstream drivers directly.
An unconventional target that still found real capital
Treating a common cold virus as a legitimate drug target for a chronic lung disease is a genuinely unconventional bet, and the fact that it attracted an oversubscribed round suggests investors think the underlying science is stronger than the pitch initially sounds on its face.
A wave of well funded, mechanistically distinct programs launching in the same year, in a category that has not seen this level of sustained attention recently, is a signal the category may be re-rating. That mirrors a broader pattern running through this issue, capital moving toward genuinely differentiated mechanisms rather than incremental improvements on existing approaches, whether in neurology, cardiometabolic care, or here in respiratory disease.
Trial data, not funding announcements, is the real signal
Both programs are still in mid-stage trials, meaning neither has produced the human efficacy data that will determine whether either mechanism actually changes COPD outcomes. Watch for trial readouts specifically, not just future funding announcements, since respiratory disease has a long history of promising mechanisms that did not hold up once tested at scale in real patients.
Also worth tracking is whether either approach, inflammation or antiviral, pulls ahead of the other in investor attention once early data starts to land, since that would likely shape where the next wave of respiratory capital flows.
